ALDEYRA THERAPEUTICS, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-33.8M | $-55.9M | $-37.5M | $-62.0M | $-57.8M | $-37.6M | $-60.8M | $-38.9M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $252.0K | $249.6K | $262.8K | $258.7K | $264.2K | $56.2K | $96.3K | $71.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $6.1M | $8.0M | $5.8M | $8.3M | $7.1M | $7.1M | $8.1M | $4.1M |
| Net Cash from Operating Activities | $-33.3M | $-43.2M | $-30.3M | $-56.6M | $-42.6M | $-37.5M | $-45.0M | $-29.9M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | $0 | $16.3K | $7.8K | — | $9.5K | $263.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $47.7M | $-44.9M | $30.0M | $-30.0M | $-7.8K | $29.0M | $18.5M | $-23.3M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $1.1M | $-171.4K | $-1.3M | $1.2M | $194.5M | $41.9M | $23.6M | $80.5M |
| Net Change in Cash | $15.5M | $-88.3M | $-1.6M | $-85.4M | $151.9M | $33.4M | $-2.9M | $27.3M |
| Free Cash Flow | — | — | $-30.3M | $-56.7M | $-42.6M | — | $-45.0M | $-30.1M |